Meyer Handelman Co. Decreases Position in Zimmer Biomet Holdings, Inc. $ZBH

Meyer Handelman Co. lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 46.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 15,759 shares of the medical equipment provider’s stock after selling 13,410 shares during the quarter. Meyer Handelman Co.’s holdings in Zimmer Biomet were worth $1,425,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Zimmer Biomet by 6.1% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 399,826 shares of the medical equipment provider’s stock worth $39,383,000 after purchasing an additional 22,992 shares in the last quarter. Inceptionr LLC acquired a new stake in Zimmer Biomet during the 3rd quarter valued at $1,217,000. PNC Financial Services Group Inc. grew its holdings in Zimmer Biomet by 9.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares in the last quarter. Wilsey Asset Management Inc. purchased a new stake in Zimmer Biomet during the 4th quarter worth $32,439,000. Finally, Dimensional Fund Advisors LP increased its stake in Zimmer Biomet by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,269,122 shares of the medical equipment provider’s stock worth $223,503,000 after buying an additional 39,146 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $90.87 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The firm’s 50-day simple moving average is $86.80 and its 200-day simple moving average is $89.97. The firm has a market cap of $17.58 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 2.66 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period last year, the firm earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be given a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ZBH shares. Wells Fargo & Company decreased their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays cut their price target on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 29th. JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Finally, Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.